Centessa Pharma drops on $250 mln share sale

Centessa Pharmaceuticals

12/11/2025 13:15

** U.S.-listed shares of Centessa Pharmaceuticals CNTA.O down 4.1% premarket at $21.61 after $250 mln overnight follow-on priced

** U.K.-based sleep disorder therapy developer late Tues announced ~11.6 mln American depositary shares at $21.50, a 4.6% discount to last sale

** Co intends to use net offering proceeds to fund continued development of its product candidates, and general corporate purposes, per the offering prospectus

** Jefferies, Leerink, Evercore and Guggenheim joint bookrunners

** CNTA has ~134.4 mln shares outstanding

** Shares on Tues finished up 0.9%, up ~35% YTD

** All 15 analysts covering CNTA are bullish with median PT of $33, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@thomsonreuters.commailto:lance.tupper@tr.com 1-646-279-6380))